SEARCH

SEARCH BY CITATION

References

  • 1
    Uchiyama T,Yodoi J,Sagawa K,Takatsuki K,Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 48192.
  • 2
    Poiesz BJ,Ruscetti FW,Gazdar AF,Bunn PA,Minna JD,Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 741519.
  • 3
    Yoshie O,Fujisawa R,Nakayama T,Harasawa H,Tago H,Izawa D,Hieshima K,Tatsumi Y,Matsushima K,Hasegawa H,Kanamaru A,Kamihira S, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99: 150511.
  • 4
    Ishida T,Utsunomia A,Iida S,Inagaki H,Takatsuka Y,Kusumoto S,Takeuchi G,Shimizu S,Ito M,Komatsu H,Wakita A,Eimoto T, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 362534.
  • 5
    Shimauchi T,Imai S,Hino R,Tokura Y. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells. Clin Cancer Res 2005; 11: 242735.
  • 6
    Blattner WA. Human retroviruses: their role in cancer. Proc Assoc Am Physicians 1999; 111: 56372.
  • 7
    Edlich RF,Arnette JA,Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000; 18: 10919.
  • 8
    Shimoyama M, Members of the Lymphoma Study Group (1984–1987). Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–1987). Br J Haematol 1991; 79: 42837.
  • 9
    Moriyama K,Muranishi H,Nishimura J,Tanaka K,Asayama R,Takita A. Immunodeficiency in preclinical smoldering adult T-cell leukemia. Jpn J Clin Oncol 1988; 4: 3639.
  • 10
    Kohno T,Yamada Y,Akamatsu N,Kamihira S,Imaizumi Y,Tomonaga M,Matsuyama T. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci 2005; 96: 52733.
  • 11
    Sansom DM,Manzotti CN,Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003; 24: 31419.
  • 12
    Walunas TL,Bakker CY,Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 254150.
  • 13
    Krummel MF,Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 45965.
  • 14
    Shinohara T,Taniwaki M,Ishida Y,Kawaichi M,Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994; 23: 7046.
  • 15
    Okazaki T,Maeda A,Nishimura H,Kurosaki T,Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting Src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 1386671.
  • 16
    Nishimura H,Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001; 22: 2658.
  • 17
    Freeman GJ,Long AJ,Iwai Y,Bourque K,Chernova T,Nishimura H,Fitz LJ,Malenkovich N,Okazaki T,Byrne MC,Horton HF,Fouser L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 102734.
  • 18
    Latchman Y,Wood CR,Chernova T,Chaudhary D,Borde M,Chernova I,Iwai Y,Long AJ,Brown JA,Nunes R,Greenfield EA,Bourque K, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 2618.
  • 19
    Brown JA,Dorfman DM,Ma FR,Sallivan EL,Munoz O,Wood CR,Greenfield EA,Freeman GJ. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 125766.
  • 20
    Day CL,Kaufmann DE,Kiepiela P,Brown JA,Moodley ES,Reddy S,Mackey EW,Miller JD,Leslie AJ,DePierres C,Mncube Z,Duraiswamy J, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 3504.
  • 21
    Petrovas C,Casazza JP,Brenchley JM,Price DA,Gostick E,Adams WC,Precopio ML,Schacker T,Roederer M,Douek DC,Koup RA. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 228192.
  • 22
    Trautmann L,Janbazian L,Chomont N,Said EA,Gimmig S,Bessette B,Boulassel MR,Delwart E,Sepulveda H,Balderas RS,Routy JP,Haddad EK, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198202.
  • 23
    Dong H,Strome SE,Salomao DR,Tamura H,Hirano F,Flies DB,Roche PC,Lu J,Zhu G,Tamada K,Lennon VA,Celis E, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793800.
  • 24
    Wintterle S,Schreiner B,Mitsdoerffer M,Schneider D,Chen L,Meyermann R,Weller M,Wiendl H. Expression of the B7-related molecule B7-H1by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003; 63: 74627.
  • 25
    Strome SE,Dong H,Tamura H,Voss SG,Flies DB,Tamada K,Salomao D,Cheville J,Hirano F,Lin W,Kasperbauer JL,Ballman KV, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 65015.
  • 26
    Dorfman DM,Brown JA,Shahsafaei A,Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 80210.
  • 27
    Chen L. Co-inhibitory molecules of the B7-28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 33647.
  • 28
    Agata Y,Kawasaki H,Nishimura Y,Ishida Y,Tsubata T,Yagita H,Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8; 76572.
  • 29
    Egen JG,Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002; 16: 235.
  • 30
    Chamber CA,Kuhns MS,Egen JG,Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 56594
  • 31
    Raimondi G,Shufesky WJ,Tokita D,Morelli AE,Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 2006; 439: 6827.
  • 32
    Matsubara Y,Hori T,Morita R,Sakaguchi S,Uchiyama T. Delineation of Immunoregulatory properties of adult T-cell leukemia cells. Int J Hematol 2006; 84: 639.
  • 33
    Chen S,Ishii N,Ine S,Ikeda S,Fujimura T,Ndhlovu LC,Soroosh P,Tada K,Harigae H,Kameoka J,Kasai N,Sasaki T, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol 2006; 18: 26977.
  • 34
    Yano H,Ishida T,Inagaki A,Ishii T,Kusumoto S,Komatsu H,Iida S,Utsunomiya A,Ueda R. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer 2007; 120: 20527.
  • 35
    Thompson RH,Dong H,Lohse CM,Leibovich BC,Blute ML,Cheville JC,Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 175761.
  • 36
    Konishi J,Yamazaki K,Azuma M,Kinoshita I,Dosaka-Akita H,Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094100.